FcRn inhibitors are biologic therapies designed to target the neonatal Fc receptor (FcRn), which plays a key role in immune system modulation by protecting immunoglobulin G (IgG) from degradation. By inhibiting this receptor, FcRn inhibitors can help treat autoimmune and inflammatory disorders by reducing pathogenic IgG levels. These therapies have shown efficacy in treating conditions like myasthenia gravis, thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and warm autoimmune hemolytic anemia.
<h3 dir="ltr">FcRn Inhibitors Epidemiology Segmentation</h3>
The Epidemiological Segmentation of FcRn Inhibitors in the 7MM (United States, EU4&mdash;Germany, France, Italy, Spain, and the United Kingdom&mdash;and Japan) from 2023 to 2034 includes:
<ul>
<li dir="ltr" aria-level="1">
Total Eligible Patient Pool by Indication
</li>
<li dir="ltr" aria-level="1">
Total Treated Patient Pool by Indication
</li>
</ul>
<h3 dir="ltr">FcRn Inhibitors Epidemiology</h3>
In 2023, the epidemiology of FcRn inhibitors for key indications in the 7MM is as follows:
<ul>
<li dir="ltr" aria-level="1">
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Approximately 21,000 patients in the United States.
</li>
<li dir="ltr" aria-level="1">
Graves&rsquo; Disease: The prevalence in the EU4 and the UK was estimated at 1,241,720 cases.
</li>
<li dir="ltr" aria-level="1">
Thyroid Eye Disease (TED): 84,000 patients across the 7MM.
</li>
<li dir="ltr" aria-level="1">
Additional conditions like myasthenia gravis, bullous pemphigoid, and warm autoimmune hemolytic anemia further contribute to the eligible patient pool for FcRn inhibitors.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/fcrn-inhibitor-competitive-landscape-and-market-forecast">FcRn Inhibitors Market</a></h3>
In 2023, the global net product revenues generated by VYVGART and VYVGART SC were:
<ul>
<li dir="ltr" aria-level="1">
USD 908 million for VYVGART
</li>
<li dir="ltr" aria-level="1">
USD 246 million for VYVGART SC
</li>
</ul>
The FcRn inhibitor market is expected to experience significant growth from 2023 to 2034, driven by continued innovation and rising demand for targeted therapies in autoimmune diseases.
<h3 dir="ltr">FcRn Inhibitors Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
Aging Population: The increasing prevalence of autoimmune diseases in the elderly is expected to drive demand for FcRn inhibitors.
</li>
<li dir="ltr" aria-level="1">
Advances in Diagnosis and Awareness: Improved diagnostic tools and greater awareness of autoimmune disorders are enabling earlier detection and treatment, contributing to market expansion.
</li>
<li dir="ltr" aria-level="1">
Emerging Therapies: Development of novel FcRn inhibitors for additional indications and improving clinical outcomes will expand their use.
</li>
</ul>
<h3 dir="ltr">FcRn Inhibitors Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
High Disease Burden: Autoimmune diseases remain prevalent with high morbidity and mortality rates, limiting therapeutic impact despite available treatments.
</li>
<li dir="ltr" aria-level="1">
Treatment Access and Affordability: The high cost of FcRn inhibitors and limited healthcare infrastructure in some regions can impede access to treatment, especially in developing markets.
</li>
</ul>
<h3 dir="ltr">FcRn Inhibitors Emerging Therapies</h3>
<ul>
<li dir="ltr" aria-level="1">
Batoclimab
</li>
<li dir="ltr" aria-level="1">
Nipocalimab
</li>
<li dir="ltr" aria-level="1">
VYVGART (Efgartigimod)
</li>
</ul>
And others.&nbsp;
<h3 dir="ltr">FcRn Inhibitors Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Immunovant
</li>
<li dir="ltr" aria-level="1">
Johnson &amp; Johnson (Innovative Medicine)
</li>
<li dir="ltr" aria-level="1">
Argenx
</li>
<li dir="ltr" aria-level="1">
UCB
</li>
<li dir="ltr" aria-level="1">
Sobi
</li>
<li dir="ltr" aria-level="1">
Vifor Pharma
</li>
</ul>
And others

FcRn Inhibitor Market

FcRn Inhibitor Market Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.